Literature DB >> 2838002

[A gastric cancer showing marked improvement (stage IV) with lentinan immunotherapy and 5-FU, MMC-chemotherapy].

M Horiguchi1, A Saito, H Sonoda.   

Abstract

A 59-year-old male undergoing an exploratory laparotomy for stage IV gastric cancer (H0P1N4S3) was treated concomitantly with Lentinan, 5-FU and MMC. The CEA values, fluoroscopic and endoscopic findings and histology by biopsy were investigated sequentially. Three months after the beginning of treatment, clinical symptoms had nearly disappeared. Body weight increase and recovery from anemia were observed. The CEA value which had shown a high preoperative level of 114.2 ng/ml decreased to 4.0 ng/ml. The marked improvement of endoscopic findings and no cancer cells were seen in several biopsy specimens. However, the condition of the patient deteriorated six months later. This patient showed clear improvement, although temporary, with immunochemotherapy.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2838002

Source DB:  PubMed          Journal:  Gan To Kagaku Ryoho        ISSN: 0385-0684


  2 in total

1.  High plasma concentration of beta-D-glucan after administration of sizofiran for cervical cancer.

Authors:  Hirokazu Tokuyasu; Kenichi Takeda; Yuji Kawasaki; Yasuto Sakaguchi; Noritaka Isowa; Eiji Shimizu; Yasuto Ueda
Journal:  Int J Gen Med       Date:  2010-10-05

2.  Intestinal anti-inflammatory activity of lentinan: influence on IL-8 and TNFR1 expression in intestinal epithelial cells.

Authors:  Yosuke Nishitani; Ling Zhang; Masaru Yoshida; Takeshi Azuma; Kazuki Kanazawa; Takashi Hashimoto; Masashi Mizuno
Journal:  PLoS One       Date:  2013-04-22       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.